These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25728850)

  • 21. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
    Lewis LD; Miller AA; Owzar K; Bies RR; Markova S; Jiang C; Kroetz DL; Egorin MJ; McLeod HL; Ratain MJ;
    Pharmacogenet Genomics; 2013 Jan; 23(1):29-33. PubMed ID: 23188068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymer-based delivery system.
    Lee SW; Yun MH; Jeong SW; In CH; Kim JY; Seo MH; Pai CM; Kim SO
    J Control Release; 2011 Oct; 155(2):262-71. PubMed ID: 21704664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.
    Ando M; Saka H; Ando Y; Minami H; Kuzuya T; Yamamoto M; Watanabe A; Sakai S; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):552-8. PubMed ID: 15856233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.
    Nieuweboer AJ; Smid M; de Graan AM; Elbouazzaoui S; de Bruijn P; Eskens FA; Hamberg P; Martens JW; Sparreboom A; de Wit R; van Schaik RH; Mathijssen RH
    Pharmacogenomics J; 2016 Nov; 16(6):519-524. PubMed ID: 26345519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of docetaxel-loaded intravenous lipid emulsion: pharmacokinetics, tissue distribution, antitumor activity, safety and toxicity.
    Zhao M; Su M; Lin X; Luo Y; He H; Cai C; Tang X
    Pharm Res; 2010 Aug; 27(8):1687-702. PubMed ID: 20552255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of granisetron on the pharmacokinetics and pharmacodynamics of docetaxel in Asian lung cancer patients.
    Miyata M; Yasuda K; Burioka N; Takane H; Suyama H; Shigeoka Y; Endo M; Kurai J; Morita M; Igishi T; Shimizu E
    Cancer J; 2006; 12(1):69-72. PubMed ID: 16613665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
    Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
    Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
    Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
    Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Dose-Attenuated Docetaxel in Asian Patients with Castrate-Resistant Prostate Cancer.
    Ang JW; Tan MH; Tay MH; Toh CK; Ng QS; Kanesvaran R
    Ann Acad Med Singap; 2017 May; 46(5):195-201. PubMed ID: 28600580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
    Salazar R; Morales S; Gil-Martín M; Aguirre E; Oaknin A; Garcia M; Callies S; Wickremsinhe ER; Benhadji KA; Llombart A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1205-15. PubMed ID: 24744161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients.
    Kita Y; Shimizu Y; Inoue T; Kamba T; Yoshimura K; Ogawa O
    Int J Clin Oncol; 2013 Aug; 18(4):718-23. PubMed ID: 22791141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
    Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
    Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
    Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):53-9. PubMed ID: 17009034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
    Iqbal S; Lenz HJ; Gandara DR; Shibata SI; Groshen S; Synold TW; Newman EM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):85-91. PubMed ID: 23712328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical pharmacology of the taxanes: implications of the differences.
    Gligorov J; Lotz JP
    Oncologist; 2004; 9 Suppl 2():3-8. PubMed ID: 15161985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of flavopiridol and docetaxel.
    El-Rayes BF; Gadgeel S; Parchment R; Lorusso P; Philip PA
    Invest New Drugs; 2006 Jul; 24(4):305-10. PubMed ID: 16683073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.